## Definition
The Healthcare Common Procedure Coding System (HCPCS) code G0087 is defined as “Colorectal cancer screening; fecal immunoassay, 1-3 simultaneous determinations.” This code is used to report laboratory tests that screen for colorectal cancer using fecal immunochemical testing, commonly referred to as FIT. Typically, the test involves analyzing stool samples to detect hidden blood, which may indicate the presence of cancer or pre-cancerous conditions, such as polyps.
Unlike traditional guaiac-based fecal occult blood tests, fecal immunochemical tests rely on antibodies to detect human hemoglobin protein in the stool. This method is deemed more specific and reduces the risk of false positives triggered by dietary and medication factors. G0087 is specifically applied in mass screening programs for colorectal cancer, which frequently target eligible individuals above a certain age or with risk factors present.
## Clinical Context
Colorectal cancer is one of the leading causes of cancer-related deaths globally, and early detection is critical for effective treatment and better outcomes. Fecal immunochemical testing is a non-invasive method for detecting blood in the stool, a common early symptom of colorectal neoplasms. HCPCS code G0087 is typically utilized in outpatient settings, including primary care clinics, laboratories, and screening programs aimed at broader population health initiatives.
G0087 is often ordered for asymptomatic individuals who fall under specific screening guidelines established by various public health authorities, such as the United States Preventive Services Task Force. This test is typically recommended for adults aged 45 and older and is repeated at regular intervals depending on the patient’s risk factors or previous screening results.
## Common Modifiers
The use of modifiers attached to HCPCS code G0087 allows further refinement or clarification about the circumstances of the service provided. One of the most commonly used modifiers is modifier -33, which represents preventive services. Modifier -33 is specifically applied without a co-payment when services are provided as part of a colorectal cancer screening, in compliance with Affordable Care Act requirements.
Another notable modifier is modifier -QW, which signifies the service performed was in accordance with Clinical Laboratory Improvement Amendments (CLIA)-waived testing. Modifier -QW is especially relevant for laboratory testing codes like G0087, where the site performing the test may not have the same certification as full clinical labs, but the test is still performed in an approved, simplified manner.
## Documentation Requirements
For appropriate billing of HCPCS code G0087, health care providers must ensure proper documentation that supports the clinical need for screening. This includes a clear record of the patient being part of an eligible population for colorectal cancer screening, such as meeting the age criteria and having no prior significant symptoms indicative of cancer. The documentation should specify that the test was performed as a routine screening and not as a diagnostic follow-up due to existing symptoms.
In addition, practitioners must retain laboratory results in the patient’s medical record, highlighting the methodology of the fecal immunochemical test. The laboratory must also document whether one, two, or three simultaneous determinations were made, per the description of the code. Failure to adhere to proper documentation can result in claims denials or delayed payments.
## Common Denial Reasons
HCPCS code G0087 claims may be denied for several reasons, often relating to billing errors or medical necessity requirements. One frequent cause of denial is the failure to use an appropriate modifier—particularly, the omission of modifier -33 when billing for preventive services under comprehensive insurance plans. Without this modifier, the patient’s insurance may incorrectly classify the service as subject to co-pays or deductibles.
Another common reason for denial involves submitting the code for an ineligible patient population, such as individuals under the recommended screening age or patients already exhibiting symptoms. Claims may also be denied when the test is performed too frequently, as many insurers limit coverage for routine colorectal screenings to a specific interval.
## Special Considerations for Commercial Insurers
When submitting claims with code G0087 to commercial insurers, it’s important to note that coverage criteria for routine colorectal cancer screening can vary significantly between payers. Although preventive screens are mandated to be covered without cost-sharing under the Affordable Care Act, some insurers may impose stricter eligibility requirements regarding age or screening intervals. It is essential to review the specific insurer’s policies prior to submitting claims to ensure compliance with coverage guidelines.
Commercial insurers also may have differing policies regarding payment for multiple simultaneous methods of colorectal cancer screening. For instance, if another form of colorectal screening, such as a colonoscopy, was also performed in the same period, the insurer may not reimburse for both tests. Therefore, careful coordination between the health care provider and payer is crucial to avoid reimbursement issues.
## Similar Codes
Several HCPCS and Current Procedural Terminology (CPT) codes relate to colorectal cancer screening, offering nuanced distinctions between various technologies and methodologies. One such similar code is CPT 82274, which also refers to a fecal occult blood test but uses different detection methods like a guaiac-based test. The main distinction is that code G0087 applies specifically to fecal immunochemical testing, while CPT 82274 refers more broadly to traditional fecal occult blood testing.
Another related code is HCPCS G0464, which describes “Colorectal cancer screening; stool-based DNA,” often used for colorectal screenings based on a combination of fecal blood detection and DNA mutation analysis. G0464 offers a broader, more comprehensive alternative to G0087 and may be requested in cases where a different technological approach is preferred or required. Therefore, each code must be selected based on the specific nature and method of testing ordered by the physician.